Medical valley micro signal: yigoonet
Jiang Zhong Pharmaceutical, which sells "Jianwei Xiaoshi Tablets", officially changed hands with China Resources.
Yesterday (10), Jiang Zhong Pharmaceutical issued the Announcement on Changing the Name and Business Scope of the Controlling Shareholder, saying that the company recently received a notice from the controlling shareholder of the company, and with the approval of Jiangxi Provincial Market Supervision Administration, the controlling shareholder completed the industrial and commercial change registration of the enterprise name and business scope on April 8, 20 19.
After the change, the name of the company was changed from "Jiangxi Jiang Zhong Pharmaceutical (Group) Co., Ltd." to "China Resources Jiang Zhong Pharmaceutical Group Co., Ltd.", and its business scope was "investment and holding management in pharmaceutical and other industries; Procurement and processing of Chinese herbal medicines. (Projects subject to approval according to law can only be operated after approval by relevant departments) "is changed to Chinese herbal medicine procurement; Production of Chinese patent medicine (not involving state secret formula); Enterprise management consulting services; Domestic trade and international trade. (Projects subject to approval according to law can only be operated after approval by relevant departments).
The successful reorganization of Jiang Zhong Pharmaceutical by China Resources Pharmaceutical Co., Ltd. means that there is another listed company in its territory, reaching four (previously there were three listed companies, namely China Resources Sanjiu, China Resources Shuanghe and Dong 'e Ejiao).
According to public information, Jiang Zhong Pharmaceutical was officially listed on 1996, focusing on the Chinese medicine industry, mainly engaged in the production, research and development and sales of over-the-counter drugs and health care products (including functional foods). The over-the-counter business of the company mainly includes Jiang Zhong brand Jianwei Xiaoshi tablets, Jiang Zhong brand lactic acid bacteria tablets, Jiang Zhong brand compound grass coral buccal tablets and other varieties, and the health care products and functional foods mainly include Chu Yuan and Shenlingcao. According to the 20 18 annual report issued by Jiang Zhong pharmaceutical co., ltd., the company achieved an operating income of17.55 million yuan in 20 18, a year-on-year increase of 0.49. The net profit attributable to owners of the parent company was 470 million yuan, a year-on-year increase of 65,438+02.55%.
In order to win this listed company, the acquisition of Jiang Zhong Pharmaceutical by China Resources Pharmaceutical began last year.
At the end of April, 2065438+08, Jiang Zhong Pharmaceutical announced that Jiang Zhong Group, the controlling shareholder, was planning major events, which might involve the change of the company's control rights.
18, 17 In May, China Resources Pharmaceutical signed a cooperation agreement with the State-owned Assets Supervision and Administration Commission of Jiangxi Province. The main content is that China Resources Medicine will carry out strategic restructuring of Jiang Zhong Group, and acquire more than 5 1% or 5 1% equity of Jiang Zhong Group by purchasing part of its equity and increasing capital in cash or assets.
2065438+On June 2, 2008, Jiang Zhong Pharmaceutical Company disclosed the abstract of the tender offer report, and China Resources Pharmaceutical Company planned to hold 56.97% equity of Jiang Zhong Pharmaceutical Company with the maximum capital of 4.278 billion yuan, becoming the controlling shareholder of Jiang Zhong Pharmaceutical Company.
On October 26th, 2065438+2009/kloc-0, the strategic reorganization of 65438+2009 China Resources Pharmaceutical Holdings and the indirect transfer of Jiang Zhong Pharmaceutical Holdings were approved by the State-owned Assets Supervision and Administration Commission of the State Council.
20 19 On February 23rd, China Resources Pharmaceutical Holdings completed the industrial and commercial change registration procedures by acquiring 5 1% equity of Jiang Zhong Group. According to the industrial and commercial change information, the registered capital of Jiang Zhong Group increased from the previous 654.38+25 million yuan to 254 million yuan, and China Resources Pharmaceutical Holdings subscribed for nearly 654.38+30 million yuan.
2065438+On February 28th, 2009, Jiang Zhong Pharmaceutical issued a tender offer report, and China Resources Pharmaceutical will issue a comprehensive tender offer to all shareholders except the controlling shareholder Jiang Zhong Group. The tender offer price is 1756 yuan/share, the number of tender offers is about 239 million shares, and the total amount of funds required is close to 4.202 billion yuan.
20 19 On April 3rd, China Resources Pharmaceutical announced the progress of its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, in its tender offer to acquire shares of Jiang Zhong Pharmaceutical. The tender offer is valid until April 2, 20 19, and the stock of Jiang Zhong Pharmaceutical was temporarily suspended on April 3, 20 19, pending the confirmation of the tender offer.
For this acquisition, some analysts believe that it is a win-win situation for China Resources Medicine and Jiang Zhong Medicine. According to public data, the market share of Jiang Zhong Pharmaceutical is about 70% in the field of invigorating stomach and promoting digestion, and 25% in the field of Chinese patent medicine throat buccal tablets, ranking second in the industry. After the acquisition, Jiang Zhong Pharmaceutical can supplement the product group of China Resources Pharmaceutical in these two areas. The short board in the river is mainly sales, and China Resources has a strong sales network and distribution channels.
It is also known that with the support of China Resources, Jiang Zhong Pharmaceutical has begun to expand its new layout and seek transformation. In terms of business structure, from relying solely on Jiang Zhong brand products such as Jianwei Xiaoshi tablets, Caoshanhu buccal tablets and lactic acid bacteria tablets in the past, it has become a business layout focusing on the existing OTC and health care products business of the headquarters. The newly merged companies Sang Hai Pharmaceutical and Jisheng Pharmaceutical merged the OTC and prescription drug business of traditional Chinese medicine; At the same time, the product approval number has increased from dozens to more than 200, covering the fields from the original gastrointestinal tract to digestive aid, upper respiratory tract extension or expansion to urinary system, digestive system, cardiovascular and cerebrovascular diseases, calming the nerves and nourishing the brain.
Wen | Medical Valley Comprehensive Report
For today's reading list, click "Read the original" at the bottom left to browse.
20 19 India medical device and biopharmaceutical inspection and precision docking tour invites you to experience. Please click here for more details.
Medical Valley: It has the most complete information source channel of medical and health industry, keeps up with policy trends and disseminates the latest industry information; Gather well-known investors at home and abroad, explore and track innovative projects, and realize rapid docking of project capital; Collect a large number of exhibition information and post-exhibition reports, focus on popular product technologies, and elaborate experts' unique opinions.
Shanghai International Medical Park, the south core area of Zhangjiang Science City and the city sub-center, looks forward to your visit and development, 021-68119996.